黑色素瘤前哨淋巴结活检列线图的临床效用
研究纳入2003至2021年单中心接受前哨淋巴结活检的2464例黑色素瘤病例,评估澳大利亚黑色素瘤研究所、纪念斯隆凯特琳癌症中心(MSK)和Friedman三种列线图的统计性能与临床效用。结果显示三种模型曲线下面积分别为0.726、0.720和0.721,仅在10%风险阈值下Friedman模型可净避免每100例患者中6.2例前哨淋巴结活检。
要点
- 三种列线图曲线下面积分别为0.726、0.720和0.721,性能相当。
- 预测阳性率低于30%时所有模型校准最佳,MSK模型低估风险。
- 10%风险阈值下仅Friedman模型可净避免每100例中6.2例活检。
核心结论
- 三种列线图在本队列中性能相当,仅Friedman模型在≤10%风险阈值下具有临床效用。
研究设计与样本
- 单中心2003至2021年接受前哨淋巴结活检的2464例黑色素瘤病例,评估三种列线图的预测概率并绘制受试者工作特征曲线和校准曲线,通过决策曲线分析评估临床效用。
主要发现
- 2464例接受前哨淋巴结活检的黑色素瘤病例中567例(23.0%)前哨淋巴结阳性。
- 澳大利亚黑色素瘤研究所、MSK和Friedman模型的曲线下面积分别为0.726(95%CI 0.702至0.750)、0.720(95%CI 0.697至0.744)和0.721(95%CI 0.699至0.744)。
- 所有模型在预测阳性率低于30%时校准最佳,MSK模型低估风险。
- 在10%风险阈值下,仅Friedman模型可正确净避免每100例患者中6.2例前哨淋巴结活检,其他模型在≤10%风险阈值下未减少净可避免的前哨淋巴结活检。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: For patients with melanoma, the decision to perform sentinel lymph node biopsy (SLNB) is based on the estimated risk of lymph node metastasis. We assessed 3 melanoma SLNB risk-prediction models' statistical performance and their ability to improve clinical decision making (clinical utility) on a cohort of melanoma SLNB cases. STUDY DESIGN: Melanoma patients undergoing SLNB at a single center from 2003 to 2021 were identified. The predicted probabilities of sentinel lymph node positivity using the Melanoma Institute of Australia, Memorial Sloan Kettering Cancer Center (MSK), and Friedman nomograms were calculated. Receiver operating characteristic and calibration curves were generated. Clinical utility was assessed via decision curve analysis, calculating the net SLNBs that could have been avoided had a given model guided selection at different risk thresholds. RESULTS: Of 2,464 melanoma cases that underwent SLNB, 567 (23.0%) had a positive sentinel lymph node. The areas under the receiver operating characteristic curves for the Melanoma Institute of Australia, MSK, and Friedman models were 0.726 (95% CI, 0.702 to 0.750), 0.720 (95% CI, 0.697 to 0.744), and 0.721 (95% CI, 0.699 to 0.744), respectively. For all models, calibration was best at predicted positivity rates below 30%. The MSK model underpredicted risk. At a 10% risk threshold, only the Friedman model would correctly avoid a net of 6.2 SLNBs per 100 patients. The other models did not reduce net avoidable SLNBs at risk thresholds of ≤10%. CONCLUSIONS: The tested nomograms had comparable performance in our cohort. The only model that achieved clinical utility at risk thresholds of ≤10% was the Friedman model.
引用
- Drebin HM, Hosein S, Kurtansky NR, et al. Clinical Utility of Melanoma Sentinel Lymph Node Biopsy Nomograms. J Am Coll Surg. 2023. PMID: 37870230. doi:10.1097/XCS.0000000000000886
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。